174 related articles for article (PubMed ID: 18325501)
1. Appropriate methods to monitor controlled ovarian hyperstimulation?
Cebesoy FB
Fertil Steril; 2008 Apr; 89(4):1025; author reply 1025-6. PubMed ID: 18325501
[No Abstract] [Full Text] [Related]
2. Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists?
Orvieto R; Rabinson J; Meltcer S; Gemer O; Anteby EY; Zohav E
Fertil Steril; 2008 Mar; 89(3):736-7. PubMed ID: 17498708
[TBL] [Abstract][Full Text] [Related]
3. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
[TBL] [Abstract][Full Text] [Related]
5. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
[TBL] [Abstract][Full Text] [Related]
6. The J-Tip Needle-Free Injection System in controlled ovarian hyperstimulation in in vitro fertilization: a pilot study.
Lavery SA; El-Shawarby SA; Turner C; Trew G
Fertil Steril; 2008 Nov; 90(5):1969-72. PubMed ID: 18166182
[TBL] [Abstract][Full Text] [Related]
7. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited.
Zarek SM; Muasher SJ
Fertil Steril; 2011 Jun; 95(8):2449-55. PubMed ID: 21550037
[TBL] [Abstract][Full Text] [Related]
8. Letrozole and gonadotropins versus luteal estradiol and gonadotropin-releasing hormone antagonist protocol in women with a prior low response to ovarian stimulation.
Elassar A; Engmann L; Nulsen J; Benadiva C
Fertil Steril; 2011 Jun; 95(7):2330-4. PubMed ID: 21514582
[TBL] [Abstract][Full Text] [Related]
9. In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle.
Kummer NE; Weitzman VN; Benadiva CA; Schmidt DW; Engmann LL; Nulsen JC
Fertil Steril; 2011 Jun; 95(8):2592-4. PubMed ID: 21292260
[TBL] [Abstract][Full Text] [Related]
10. Degrees of uncertainty--"statistically insignificant".
Claman P
Fertil Steril; 2008 Oct; 90(4):1331; author reply 1331. PubMed ID: 18793767
[No Abstract] [Full Text] [Related]
11. Agonist or antagonist: what is preferable for in vitro fertilization?
Ben-Rafael Z
Gynecol Endocrinol; 2012 Mar; 28 Suppl 1():18-21. PubMed ID: 22394299
[No Abstract] [Full Text] [Related]
12. Endometrial thickness is related to miscarriage rate, but not to the estradiol concentration, in cycles down-regulated with gonadotropin-releasing hormone antagonist.
Detti L; Yelian FD; Kruger ML; Diamond MP; Rode A; Mitwally MF; Puscheck EE
Fertil Steril; 2008 Apr; 89(4):998-1001. PubMed ID: 17678904
[TBL] [Abstract][Full Text] [Related]
13. Can FSH co-trigger prevent OHSS?
Rosen MP; Meldrum DR
Fertil Steril; 2012 Mar; 97(3):534-5. PubMed ID: 22285746
[TBL] [Abstract][Full Text] [Related]
14. To add GnRH antagonists to controlled ovarian stimulation in management of subfertile couples with IUI may not have additional effect in terms of clinical pregnancy rates.
Kelekci S
Fertil Steril; 2011 Aug; 96(2):e133; author reply e134. PubMed ID: 21669412
[No Abstract] [Full Text] [Related]
15. Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for in vitro fertilization.
Orvieto R; Laufer N
Fertil Steril; 2014 Nov; 102(5):1254-5. PubMed ID: 25282471
[No Abstract] [Full Text] [Related]
16. Ovarian stimulation for in vitro fertilization in patients with endometriosis.
Zikopoulos K; Kolibianakis EM; Devroey P
Acta Obstet Gynecol Scand; 2004 Jul; 83(7):651-5. PubMed ID: 15225190
[TBL] [Abstract][Full Text] [Related]
17. Changes in long luteal protocol affects the number of days of stimulation: evolution of an assisted reproductive technology practice.
Palmer CB; Forstein DA; Higdon HL; Boone WR
J Reprod Med; 2011; 56(7-8):308-12. PubMed ID: 21838160
[TBL] [Abstract][Full Text] [Related]
18. Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting.
Ho Yuen B; Nguyen TA; Cheung AP; Leung PC
Fertil Steril; 2009 Aug; 92(2):499-507. PubMed ID: 18706551
[TBL] [Abstract][Full Text] [Related]
19. Repeated in vitro fertilization cycle attempts in patients undergoing controlled ovarian hyperstimulation with use of gonadotropin-releasing hormone antagonists.
Rabinson J; Ashkenazi J; Homburg R; Meltcer S; Anteby EY; Orvieto R
Fertil Steril; 2009 Apr; 91(4 Suppl):1473-5. PubMed ID: 18937940
[TBL] [Abstract][Full Text] [Related]
20. Poor responder protocols for in-vitro fertilization: options and results.
Loutradis D; Vomvolaki E; Drakakis P
Curr Opin Obstet Gynecol; 2008 Aug; 20(4):374-8. PubMed ID: 18660689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
